Host reverse transcriptase likely required to maintain persistent dengue virus infections in C6/36 insect cells

preprint OA: closed
📄 Open PDF View at publisher

Abstract

ABSTRACT C6/36 cells challenged with Dengue virus serotype 2 (DENV-2 strain NGC) show initial cytopathic effects (CPE) they overcome within 3 split passages and resume normal growth despite persistent infection with DENV-2. We hypothesized that tolerated persistent infections also required persistent host reverse-transcriptase (HRT) activity, and this was subsequently proven using the RT inhibitor AZT (azidothymidine, a nucleoside analogue antiretroviral drug) to treat C6/36 cells challenged with DENV-1. We confirmed this using the RT inhibitor tenofovir disoproxil fumarate (TDF) with C6/36, U4.4cells challenged with DENV-1. However, it has never been determined whether the persistently tolerated infections are also dependent on persistent HRT activity. This brief report reveals that persistent HRT activity is required to maintain persistent DENV-2 infections. Specifically, TDF treatment (0.1 mM) revealed minor toxicity to naive C6/36 cells but led to cell death instead of accommodation upon concomitant challenge with DENV-2, as previously reported for DENV-1. However, TDF treatment of stable, grossly normal C636 cell cultures persistently infected with DENV-2 for up to 30 split passages reverted to CPE, supporting our earlier hypothesis that persistent host RT activity is also required to maintain persistent infections. This is a practical tool for research applications in virology of crustaceans and insects for screening living, grossly healthy, imported animals for listed viral pathogens.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-05-19T01:45:01.086888+00:00